select publications

aromatase inhibitors in the breast cancer continuum

ATAC Trialists’ Group. Pharmacokinetics of anastrozole and tamoxifen alone and in combination during adjuvant endocrine therapy for early breast cancer in postmenopausal women: A sub-protocol of the “Arimidex(r) and Tamoxifen Alone or in Combination” (ATAC) trial. Br J Cancer 2001;85(3):317-24. Abstract

Baum M. The ATAC (Arimidex, Tamoxifen, Alone or in Combination) adjuvant breast cancer trial in post-menopausal women. Breast Cancer Res Treat 2001;69(3):Abstract 8.

Celio L et al. Premenopausal breast cancer patients treated with a gonadotropin-releasing hormone analog alone or in combination with an aromatase inhibitor: A comparative endocrine study. Anticancer Res 1999;19:2261-8. Abstract

Dixon JM et al. The effects of neoadjuvant anastrozole (Arimidex) on tumor volume in postmenopausal women with breast cancer: A randomized, double-blind, single-center study. Clin Cancer Res 2000;6(6):2229-35. Abstract

Dixon JM et al. Lessons from the use of aromatase inhibitors in the neoadjuvant setting. Endocrine-Related Cancer 1999;6(2):227-30. Full Text

Dixon JM et al. Letrozole as primary medical therapy for locally advanced and large operable breast cancer. Breast Cancer Res Treat 2001;66:191-9. Abstract

Elisaf MS et al. Effect of letrozole on the lipid profile in postmenopausal women with breast cancer. Eur J Cancer 2001;37(12):1510-13. Abstract

Ellis MJ et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptorpositive primary breast cancer: Evidence from a phase III randomized trial. J Clin Oncol 2001;19:3808-16. Abstract

Forward D et al. Combined use of goserelin (Zoladex) and anastrozole (Arimidex) in premenopausal women with metastatic breast cancer (MBC). Proc ASCO 2000;Abstract 582.

Geisler J et al. Influence of neoadjuvant anastrozole (Arimidex) on intratumoral estrogen levels and proliferation markers in patients with locally advanced breast cancer. Clin Cancer Res 2001;7:1230-6. Abstract

Goss PE, Strasser K. Aromatase inhibitors in the treatment and prevention of breast cancer. J Clin Oncol 2001;19:881-94. Abstract

Hamilton A, Volm M. Nonsteroidal and steroidal aromatase inhibitors in breast cancer. Oncology (Huntingt) 2001;15:965-72; discussion 972, 977-9. Abstract

Howell A et al. Where do selective estrogen receptor modulators (SERMs) and aromatase inhibitors (AIs) now fit into breast cancer treatment algorithms? J Steroid Biochem Mol Biol 2001;79:227-237. Abstract

Ingle JN. Aromatase inhibition and antiestrogen therapy in early breast cancer treatment and chemoprevention. Oncology (Huntingt) 2001;15:28-34. Abstract

Mamounas EP. Adjuvant exemestane therapy after 5 years of tamoxifen: Rationale for the NSABP B-33 trial. Oncology (Huntingt) 2001;15(5 Suppl 7):35- 39. Abstract

Martinetti A et al. The luteinising hormone-releasing hormone analogue triptorelin with or without the aromatase inhibitor formestane in premenopausal breast cancer: Effects on bone metabolism markers. J Steroid Biochem Mol Biol 2000;75:65-73. Abstract

Milla-Santos A et al. Anastrozole (A) as neoadjuvant (NEO) therapy for hormone-dependent locally advanced breast cancer (LABC) in postmenopausal (PM) patients (pts). Breast Cancer Res Treat 2001;Abstract 302.

Mouridsen H et al. Superior efficacy of letrozole versus tamoxifen as firstline therapy for postmenopausal women with advanced breast cancer: Results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol 2001;19:2596-606. Abstract

Nabholtz JM et al. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: Results of a North American multi-center randomized trial. J Clin Oncol 2000;18(22):3758-67. Abstract

Ragaz J. Adjuvant trials of aromatase inhibitors: Determining the future landscape of adjuvant endocrine therapy. J Steroid Biochem Mol Biol 2001;79:133-41. Abstract

Sverrisdottir A et al. Bone mineral density in premenopausal patients in a randomized trial of adjuvant endocrine therapy (ZIPP-TRIAL). Proc ASCO 2001;Abstract 96.

Toi M et al. Aromatase and aromatase inhibitors. Breast Cancer 2001;8(4):329- 32. Abstract

use of bisphosphonates to preserve health

Ali SM et al. Safety and efficacy of bisphosphonates beyond 24 months in cancer patients. J Clin Oncol 2001;19:3434-7. Abstract

Baran D. Osteoporosis. Efficacy and safety of a bisphosphonate dosed once weekly. Geriatrics 2001;56:28-32. Abstract

Diel IJ, Mundy GR. Bisphosphonates in the adjuvant treatment of cancer: Experimental evidence and first clinical results. International Bone and Cancer Study Group (IBCG). Br J Cancer 2000;82:1381-6. Abstract

Harris ST et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: A randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 1999;282:1344-52. Abstract

Hillner BE et al. American Society of Clinical Oncology guideline on the role of bisphosphonates in breast cancer. American Society of Clinical Oncology Bisphosphonates Expert Panel. J Clin Oncol 2000;18:1378-91. Abstract

Paterson AH. Adjuvant bisphosphonate therapy: The future. Semin Oncol 2001;28:81-5. Abstract

Reid IR et al. Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med 2002;346:653-61. Abstract

Rosen CJ. Treatment of postmenopausal osteoporosis: An evidence-based approach. Rev Endocr Metab Disord 2001;2:35-43. Abstract

Theriault RL, Hortobagyi GN. The evolving role of bisphosphonates. Semin Oncol 2001;28:284-90. Abstract

Van Poznak C. How are bisphosphonates used today in breast cancer clinical practice? Semin Oncol 2001;28(4 Suppl 11):69-74. Abstract

Woo T, Adachi JD. Role of bisphosphonates and calcitonin in the prevention and treatment of osteoporosis. Best Pract Res Clin Rheumatol 2001;15:469-81. Abstract

Home · Search